Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH.

导出 LinkOut

翻译打印收藏纠错

第一作者： Shuyan,Zhou

第一单位： Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

作者： Shuyan,Zhou ^[1] ; Qiangsheng,Zhang ^[1] ; Honglin,Yang ^[1] ; Yongxia,Zhu ^[2] ; Xiang,Hu ^[1] ; Guoquan,Wan ^[1] ; Luoting,Yu ^[3]

作者单位： Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. ^[1] Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. ^[2] Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: yuluot@scu.edu.cn. ^[3]

关键词 Asthma COPD Epigenetics Lung cancer Pulmonary fibrosis Pulmonary hypertension Type I PRMTs

主题词人类(Humans);肺纤维化(Pulmonary Fibrosis);高血压, 肺性(Hypertension, Pulmonary);肺肿瘤(Lung Neoplasms);肺疾病, 慢性阻塞性(Pulmonary Disease, Chronic Obstructive);哮喘(Asthma)

DOI 10.1016/j.lfs.2024.122538

PMID 38428571

发布时间 2024-03-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交